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SUMMARY – Glioblastoma multiforme (GBM) is caused by the central nervous system-derived 
glial cells, and represents the most common (50%-60%) form of primary brain tumors. Th e aim of this 
study was to investigate the in vitro eff ects of selenium on human GBM cells. In the present study, 
GMS-10 and DBTRG-05MG human GBM cell lines were used as a model to examine selenium 
entering the cell, cell proliferation, cytotoxicity, DNA fragmentation and Ki-67 protein expression in 
selenomethionine treated and non-treated groups. Seleno-L-methionine (SeMet) as the organic 
source of selenium exerted eff ects on cell proliferation and cytotoxicity, as assessed with WST-1 and 
lactate dehydrogenase (LDH) tests, respectively. Apoptosis was assessed by DNA fragmentation with 
an enzyme-linked immunosorbent assay. Ki-67 protein expression was determined by Western blot-
ting, while selenium measurements were performed in the supernatants and lysates by using Graphite 
Furnace Atomic Absorption Spectrometry. Th is is the fi rst study to examine the eff ects of SeMet on 
cell proliferation and death in GMS-10 and DBTRG-05MG cells. Both GBM cell lines responded 
to SeMet in a dose- and time-dependent manner. WST-1 test showed that low-dose SeMet treat-
ment (50 and 100 μM) increased cell proliferation. Analysis of intracellular SeMet levels by using 
AAS showed results consistent with viability and cytotoxicity tests. SeMet treatment for 72 h caused 
increased DNA fragmentation in both cell lines. In conclusion, our results suggest that SeMet in-
duces cell death at high doses, while increasing cell proliferation at low doses. In the view of the data 
obtained in this investigation, further studies focusing on the possibility of using SeMet against dif-
ferent types of GBM and in combination with prospect synergic compounds are considered to be 
worthwhile.
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Introduction
Selenium is an essential trace element and an ex-
traordinary element1,2. Its own codon enables its incor-
poration into proteins as selenocysteine3. Selenium 
functions in antioxidant mechanisms, immune sys-
tems, detoxifi cation mechanisms, infl ammation, male 
fertility, and also exerts anti-cancer eff ects4. Several 
studies have shown that certain selenium compounds, 
such as selenite and seleno-L-methionine, have roles 
as chemopreventive agents in diff erent cancers, includ-
ing prostate, melanoma, lung, esophageal and gastric-
cardia cancers5-7.
Glioblastoma multiforme (GBM) is the most ag-
gressive brain cancer due to its capacity of rapid inva-
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sion and its strong resistance to therapy8. Median sur-
vival is 10 to 12 months9. Some patients can live up to 
14 months10,11. Several reports have shown that treat-
ment with antioxidants is benefi cial in preventing tu-
mor growth. Recently, temozolomide, bevacizumab, 
and other alkylating agents are used in the treatment 
of glioblastoma, but drug resistance is the most impor-
tant problem12,13. To overcome this therapeutic chal-
lenge, new approaches involving a combination of an-
ti-cancer drug and antioxidant treatment have been 
developed14.
Previous studies have investigated, both in vitro 
and in vivo, the preventive and therapeutic eff ects of 
selenium on diff erent cancers, including prostate5,15, 
lung16, colon17, breast7, melanoma18, and various brain 
tumors19-22. Inorganic forms of selenium, including so-
dium selenite and sodium selenate, have been used in 
these studies.
To our knowledge, seleno-L-methionine (SeMet), 
the organic form of selenium, has not been tested in 
any study. We hypothesized that SeMet would be ef-
fective in controlling cell proliferation and apoptotic 
cell death. Here, we investigated, on two diff erent hu-
man GBM cell lines, the eff ects of SeMet on prolif-
eration, cytotoxicity, and Ki-67 protein expression. In 
addition, correlation with the amount of selenium en-
tering the cell (following treatment with diff erent 
doses of SeMet) was also evaluated.
Materials and methods
Test chemicals
Seleno-L-methionine (MW 196.11 g/mol, CAS 
Number 3211-76-5; Sigma, USA) was dissolved in 
distilled water. Th en, the solution was fi ltered and di-
luted as required. All dilutions were carried out using 
the medium. All treatments were carried out at fi nal 
concentrations of 50, 100, 500 and 1000 μM.
Cell culture
Adherent human GBM cells, GMS-10 and 
 DBTRG-05MG, were obtained from the German 
Collection of Microorganisms and Cell Cultures 
(DSMZ). GMS-10 cells were cultured in Dulbecco’s 
Modifi ed Eagle’s Medium (DMEM, D6046; Sigma; 
USA), while DBTRG-05MG cells were cultured in 
RPMI 1640 (Hyclone, Th ermo Scientifi c; USA) sup-
plemented with 10% fetal calf serum (Biological In-
dustries, Israel), 1% L-glutamine (G7513; Sigma; 
USA), and 1% penicillin-streptomycin (P4333; Sigma; 
USA) at 37 °C in 95% air and 5% CO
2 
incubator23,24. 
Cells were trypsinized at a split ratio of 1:2 or 1:3.
SeMet treatment
Both cell lines were treated with diff erent concen-
trations of SeMet (50-1000 μM) for 24, 48 and 72 h. 
Afterwards, cell survival was assessed qualitatively by 
light microscopy.
Cell viability assay
Th e inhibition of cell growth was determined by 
[2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
fophenyl)-2H-tetrazolium] kit (WST-1 05 015 944 
001, Roche). All GBM cells were seeded on 96-well 
plates (1x104 cells/well) and treated with 50, 100, 500 
and 1000 μM SeMet for 24, 48 and 72 h. Th en, 10 μL 
of WST-1 stock solution was added to each well. Cells 
were incubated at 37 °C for 0.5-4 h. After incubation, 
cell viability was assayed by measuring the absorbance 
at 440 nm on a microplate reader (Bio-Tek Instru-
ments, Inc., USA). Th e results were expressed as mean 
optical density (OD) of experimental groups (n=5) vs. 
control (non-treated cells). Th e mean OD of the con-
trol group was set to represent 100% cell  viability25.
Cell death assay
Cell death was analyzed by using lactate dehydro-
genase (LDH) assay (LDH 11 644 793 001, Roche). 
Quantifying the amount of LDH in the medium from 
dead cells and dividing the result by the total amount 
of LDH in the medium and cell lysate in the sample 
calculated the cell cytotoxicity percentage. Cell cyto-
toxicity results were expressed as the percentage of 
LDH released. All GBM cells were seeded on 96-well 
plates (1x104 cells/well) and treated with 50, 100, 500 
and 1000 μM SeMet for 24, 48 and 72 h. Th en, a 
10-μL lysis solution was added to the wells to achieve 
maximal release in maximal group cells. Cells were in-
cubated at 37 °C for 2 h for lysis. After incubation, 
LDH working solution was added to each well (super-
natants without cell) and LDH released from the me-
dium was detected by measuring absorbance at 490 
nm using a microplate reader (Bio-Tek Instruments, 
Inc., USA)26.
Duygu Harmanci et al. Eff ects of selenium in glioblastoma multiforme
50 Acta Clin Croat, Vol. 56, No. 1, 2017
Cell death ELISA
Apoptosis was assessed by DNA fragmentation 
with an enzyme-linked immunosorbent assay (Cell 
Death ELISA Plus Kit 11774425001, Roche). Briefl y, 
1x104 cells/well were seeded on 96-well plates and 
treated with 50, 100, 500, and 1000 μM SeMet for 24, 
48 and 72 h. Th e plate was centrifuged at 600 g at 4 °C 
for 10 minutes and then the supernatants were re-
moved. Th e cell pellet containing apoptotic bodies was 
lysed with 0.2 mL of a lysis buff er (cell death ELISA 
Plus, Roche) and incubated for 30 minutes at room 
temperature. Cell lysate solutions (20 μL) were placed 
in duplicate into the wells of the streptavidin-coated 
microplate, to which 80 μL of the immunoreagent 
containing a mixture of anti-histone-biotin and anti-
DNA-POD was added. Th e plate was covered with an 
adhesive cover foil and incubated for 2 h at 25 °C in a 
shaking incubator at 300 rpm. During the incubation 
period, the anti-histone antibody binds to the histone 
component of the nucleosomes and simultaneously 
captures the immunocomplex to the streptavidin-
coated microplate via its biotinylation. At the same 
time, the anti-DNA-POD antibody reacts with the 
DNA component of the nucleosomes. Th e unbound 
antibodies were washed with the incubation buff er. 
Th e amount of nucleosomes retained by the POD in 
the immunocomplex, corresponding to the extent of 
apoptosis was quantitatively determined photometri-
cally with ABTS (2,2’-azinobis-3-ethyl-benzothiazo-
line-6-sulfonic acid) as substrate, using a microplate 
reader at a wavelength of 405 nm and reference wave-
length of 490 nm. Th e enrichment of mono- and oli-
gonucleosomes in the cytoplasm of the apoptotic cells 
is due to the fact that DNA degradation occurs several 
hours before the plasma membrane breakdown. Quan-
tifying the average OD from dead cells and dividing 
the result by that of average control cells yielded the 
enrichment factor.
Selenium measurement
Cell lysates and supernatants, which were obtained 
from the cell lines after incubation, were collected for 
selenium measurements, which were done by using 
Graphite Furnace Atomic Absorption Spectrometry 
(GFAAS). After incubation, cell media were collected 
and transferred to sterile falcons and the cells were 
scraped with a cell scraper. Th e 1000-ppm selenium 
standard (Titrisol Merck) solution was diluted to 1 
ppm in 0.1 M HCl and then prepared to buff er stock 
concentrations in the range of 25-800 μg/L. All these 
buff er stock solutions were diluted to working concen-
trations in the range of 5-200 μg/L with the matrix 
modifi er which was composed of 190 mg palladium 
nitrate and 60 mg magnesium nitrate, 200 μL triton 
X-100 dissolved in 100 mL 0.1 M HCl. Before ana-
lysis, cell lysates were diluted (1:100) with the matrix 
modifi er. Th e matrix modifi er was used as blank. 
All standards and samples were then placed in the 
auto sampler vial for GFAAS analysis. Th e sample in-
jection volume was 20 μL. Selenium was detected at 
196 nm27-29.
Western blot
Following SeMet incubation, the cell lines were 
lysed in lysis buff er (50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 20 mM MgCl
2
, 1% Nonidet P-40, 0.1% 
sodium dodecyl sulfate (SDS), and 1 mM PMSF, 
aprotinin (1 μg/mL) and leupeptin (1 μg/mL)). After 
the cells had been lysed, the protein concentrations 
were measured using a BCA protein assay kit (Pierce 
BCA Protein Assay Kit 23225, Th ermo Scientifi c). 
Equal amounts of total cellular protein samples (15 
μg) were separated on a 6% SDS-polyacrylamide gel at 
100 V and transferred onto a PVDF membrane for 
2 h at 200 mA (Atto). Th e membranes were incubated 
with 5% non-fat dry milk and 3% BSA, specifi c pri-
mary antibodies at 1:250 and 1:500 directed to either 
Ki-67 (Santa Cruz, Cat No. sc-7844) and calnexin 
(Santa Cruz, Cat No. sc-6465) overnight at 4 °C, fol-
lowed by incubation with appropriate HRP conjugat-
ed secondary antibodies (donkey anti-goat IgG-
Horseradish Peroxidase Conjugated Affi  nity Purifi ed 
Antibody, Santa Cruz, Cat No. sc-2020) at 1:1000 di-
lution in PBS for 1 h at room temperature and subse-
quent chemiluminescent detection using standard 
quality x-ray fi lms30.
Statistical analysis
All data were expressed as mean ± SD and corre-
sponded to the results of at least three independent 
experiments. Th e average of fi ve wells was taken for 
each parameter. Th e cells treated with the medium 
served as control (100% viable) and the remaining 
samples were expressed as viability percentage decrease 
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or increase as compared with the control. Kolmogo-
rov-Smirnov test was used to assess whether the vari-
ables fi tted normal distribution and showed a non-
normal distribution. One-way ANOVA was used to 
analyze diff erences among these non-normally dis-
tributed groups. Pearson’s correlation test was used to 
determine correlation among experimental parame-
ters. P values <0.05 were considered as statistically sig-
nifi cant. SPSS v.19.0 (Chicago, IL, USA) was used for 
statistical analysis.
Results
SeMet treatment suppresses GBM cell proliferation 
in a dose- and time-dependent manner
Two human GBM cell lines were treated with in-
creasing concentrations of SeMet for 24, 48 and 72 h. 
Th en, cell viability was assessed by the WST-1 assay. 
As shown in Figure 1A and B, SeMet stimulated pro-
liferation of cell lines in a dose-dependent manner. For 
the GMS-10 cell line, low doses (50 μM and 100 μM) 
were found to induce proliferation at 24 h (Fig. 1A). 
We did not fi nd signifi cant diff erence between the Se-
Met treated two cell lines for 24 h, but a signifi cant 
diff erence (p<0.05) was found for 48 h and 72 h (Fig. 
1). After 72-h SeMet treatment, the IC
50 
values were 
500±200 μM for GMS-10 and 500±100 μM for DB-
TRG-05MG.
SeMet treatment induces apoptosis in GBM cells
Th e LDH assay showed that high dose SeMet 
treatment (500 μM and 1000 μM) induced cell death 
at 24 h. After 72 h, 50 μM SeMet resulted in 2.08±
0.45% increase, 100 μM in 13.26±0.76% increase, 500 
μM in 35.52±1.37% increase and 1000 μM in 50.10±
2.29% increase in cell death for the DBTRG-05MG 
cell line compared with control. For the GMS-10 cell 
line, 50 μM SeMet resulted in no death, whereas 100 
μM resulted in 3.99±0.65%, 500 μM in 10.0±0.89% 
and 1000 μM in 20.96±1.90% increase in cell death 
compared with control. Furthermore, we found nega-
tive correlation between the results of the LDH assay 
and WST-1 assay. Th e results of the LDH assay cor-
related negatively with the results of the WST-1 assay. 
Pearson’s correlation test results and the related r and p 
values are indicated in Table 1.
DNA fragmentation: apoptotic eff ects of SeMet
DNA fragmentation analysis showed that SeMet 
induced apoptosis in both GBM cell lines after 72-h 
incubation. To quantify and further support the fi nd-
ing that SeMet treatment causes cell death in GBM 
cells, we performed cell death detection by ELISA. 
Compared with controls, treatment of GMS-10 cells 
with SeMet at 500 μM and 1000 μM concentrations 
resulted in 2.94- and 4.03-fold increase in the induc-
tion of apoptosis, respectively.
GMS-10 and DBTRG-05MG cells were treated with diff erent doses of SeMet and cell proliferation was assayed at diff erent time points: 
(A) WST-1 assay of cell proliferation of GMS-10 cells treated with four diff erent doses of SeMet using 24 h, 48 h, and 72 h incubation 
times; (B) WST-1 assay of cell proliferation of DBTRG-05MG cells treated with four diff erent doses of SeMet. Th e results were expressed 
as the mean optical density (OD) of experimental groups (n=5) vs. control (non-treated cells). Th e mean OD of the control group was set 
to represent 100% cell viability. Data represent the mean of three independent experiments compared with control group (**p<0.01, 
*p<0.05).
 Fig. 1. Seleno-L-methionine (SeMet) suppresses glioblastoma multiforme (GBM) cell proliferation in a dose- 
and time-dependent manner.
A B
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A (a) A (b) A (c)
B (a) B (b) B (c)
C (a) C (b) C (c)
D (a) D (b) D (c)
(A) GMS-10 and (B) DBTRG-05MG cells were treated with increasing concentrations of SeMet, and cell death was assayed at diff erent 
time points: (a) 24 h, (b) 48 h and (c) 72 h; quantifi cation of apoptosis in (C) GMS-10 and (D) DBTRG-05MG cell lines induced by 
SeMet at diff erent time points: (a) 24 h, (b) 48 h and (c) 72 h; quantifying the average optical density (OD) from dead cells and dividing 
the result by the average control cells yielded the enrichment factor. Data are presented as mean ± SD (n=5) (*p<0.05, **p<0.01 compared 
with control group).
Fig. 2. Seleno-L-methionine (SeMet) triggers apoptotic cell death in a dose-dependent manner.
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Analysis of intracellular and extracellular 
selenium levels
Selenium uptake of the cells was assessed by mea-
suring selenium levels in the supernatants (extracellu-
lar) and lysates (intracellular) by GFAAS. At each 
dose, SeMet uptake was highest at 48 h. However, 
there was no signifi cant diff erence compared with the 
control group.
Ki-67 protein expression
Th e SDS-PAGE and Western blotting determined 
protein levels of Ki-67 following SeMet treatment. 
Ki-67 band images were shown in the GMS-10 cells 
at 24 h (UVP BioImaging System, UK).
Discussion and Conclusions
Th e ‘magic bullet theory’ proposed by Paul Ehrlich 
a century ago still remains valid in the treatment of 
cancer. According to Ehrlich, the magic bullet is a 
compound that targets a single certain oncoprotein in 
a highly specifi c fashion and does not damage healthy 
cells31. Today, current research is focused on targeted 
molecular treatment alternatives. Th is situation is valid 
for GBM. Th e development of drug resistance is a 
common condition in GBM. Th e most important 
problem with drugs is associated with those that can-
not pass the blood-brain barrier32. Selenium can cross 
the blood-brain barrier and selenoprotein P is ex-
pressed in the brain33. Th e chemical form of selenium 
A (a) A (b)
B (a) B (b)
Fig. 3. (A) Seleno-L-methionine (SeMet) levels in GMS-10 (a) and DBTRG-05MG (b) cell lysates at 24 h, 48 h 
and 72 h (**p<0.01, *p<0.05); (B) SeMet levels in GMS-10 (a) and DBTRG-05MG (b) cell supernatants at 24 h, 
48 h and 72 h (**p<0.01, *p<0.05).
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is signifi cant. Inorganic forms of selenium are more 
toxic than organic forms of selenium. Selenomethio-
nine is an organic form of selenium possessing anti-
cancer properties. First data came from the Nutrition-
al Prevention of Cancer (NPC) study, which indicated 
that selenium compounds have chemopreventive 
properties, but then the SELECT study has reported 
debate on the issue34.
Th e GMS-10 glioblastoma cells used are cancerous 
brain cells derived from a GBM patient23. DBTRG-
05MG cells were obtained from a GBM patient hav-
ing undergone surgery after chemotherapy and radio-
therapy24. GMS-10 cells are null for p53 gene, but 
DBTRG-05MG cells have not lost their heterozygos-
ity for the p5323,24. After 24-h SeMet treatment, two 
tumor cells were aff ected diff erently. Th e 50 μM and 
100 μM SeMet treatment of GMS-10 cells for 24 h 
unexpectedly exerted proliferative activity, but under 
these conditions DBTRG-05MG cells were not af-
fected. Interesting enough, in a way contrary to the 
nature of antioxidants, SeMet did not fi ght the cancer 
cells at 50-μM and 100-μM doses. Similarly, Sayin et 
al. demonstrated that antioxidants accelerated lung 
cancer progression in mice35. In this study, this diff er-
ence may have resulted from diff erences in p53 status.
In this investigation, SeMet treatment decreased 
cell proliferation and showed cytotoxicity in a dose- 
and incubation period-dependent manner in both cell 
lines (except for 50 μM and 100 μM SeMet treatment 
of GMS-10 cells for 24 h). Furthermore, these param-
eters correlated to a large extent with the level of 
 SeMet having entered the cells.
Previous studies have shown that SeMet aff ected 
diff erent cell types at diff erent concentrations and in-
cubation times. Redman et al.36 found that IC
50
 levels 
of 45 μM SeMet for MCF-7/S cells, 50 μM SeMet 
for UACC-375 cells, 130 μM SeMet for HT-29 cells, 
40 μM SeMet for DU-145 cells, 65 μM SeMet for 
A549 cells and 1 mM SeMet for fi broblast cells inhib-
ited 50% of the growth. Suzuki et al.37 applied SeMet 
in the range of 10-1000 μM to HSC-3, HSC-4, A549 
and MCF-7. In the present study, the IC
50
 values for 
SeMet were 500±200 μM for GMS-10 and 500±100 
μM for DBTRG-05MG. Given that GBM is the 
most aggressive and resistant primary brain tumor, 
such higher values are expected for GBM. Th e amount 
of selenium daily intake for normal people is 55 to 70 
mg/day. Th e body can tolerate maximum selenium 
level of 400 mg/day38. Th e doses used in this study 
were slightly higher than the recommended daily al-
lowance, but they were still within the tolerable range.
In reviewing the literature, Zhu et al.21 showed that 
selenite (0.01-100 μM) inhibited cell growth on C6 
Fig. 4. (A) Protein bands of Ki-67 determined by 
Western blot performed on the GMS-10 cell line, 
as well as those of calnexin. From left to right: bands 
show untreated control and samples treated with 
50-1000 μM SeMet for 24 h; (B) densitometric analysis 
of the bands normalized with calnexin.
A
B
Table 1. Pearson’s correlation analysis of cell death and cell proliferation after seleno-L-
methionine (SeMet) treatment
24 h 48 h 72 h
r p r p r p
GMS-10 -0.505 <0.05 -0.821 <0.01 - 0.934 <0.01
DBTRG-05MG -0.809 <0.01 -0.845 <0.01 - 0.941 <0.01
GMS-10 and DBTRG-05MG = human glioblastoma multiforme cell lines
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rat and A172 human glioblastoma cells for 24, 48 and 
72 h. Th ey also determined that A172 cells responded 
more sensitively than C6 cells. In another study, Zhu et 
al.20 showed that selenite induced apoptosis on A172 
and T98 human glioblastoma cells. In this study, we 
found that after 24-h and 48-h SeMet treatment, DB-
TRG-05MG cell death increased signifi cantly at high 
doses (500 and 1000 μM), but GMS-10 cells were not 
killed by SeMet after 24 h, whereas they were killed at 
the 500 μM dose signifi cantly after 48-h incubation. 
After 72-h SeMet incubation, DBTRG-05MG cell 
death increased at 100, 500 and 1000 μM doses sig-
nifi cantly, and GMS-10 cells were killed by SeMet on 
the same doses but not signifi cantly. As a result of the 
WST-1 and LDH assays, negative correlation was 
found between the proliferation and cytotoxicity fi nd-
ings and these parameters correlated to a large extent 
with the level of SeMet entering the cells. Th e highest 
SeMet level in both cell lines was measured after 48-h 
treatment. Th ese fi ndings correspond to the results of 
proliferation assays and suggest that SeMet cytotoxic-
ity appears to be explained in part by the induction of 
apoptosis. Interestingly, we observed a signifi cant in-
crease in apoptosis in both cell lines. Th is condition 
may be related to the cell p53 status and the develop-
ment of SeMet resistance in GMS-10 cells. Seo et al.39 
showed that SeMet could activate the p53 protein by a 
redox mechanism and SeMet diff erentially aff ected 
cells wild type or null for p53 genes. In the view of 
such information, our data must be supported by new 
experiments such as siRNA transfection and apoptosis 
assays.
Ki-67 is a well-known proliferation marker, such as 
cyclin E, cyclin D and proliferating cell nuclear anti-
gen (PCNA)36. Previous studies evaluated Ki-67 pro-
tein levels by immunohistochemistry, ELISA or West-
ern blotting40-42. Jin et al.43 showed that Ki-67 was as-
sociated with cell growth and regulating proliferation 
in GBM. In the present study, Ki-67 band images were 
determined on GMS-10 cells at 24 h and also at 48 h, 
but at 48 h and 72 h reproducible band images were 
not achieved. Th ese fi ndings suggest that Ki-67 is one 
of the examples of the proliferation signature in GBM, 
but further studies are needed to evaluate Ki-67 pro-
tein levels with other components of cellular prolifera-
tion signaling.
Th is is the fi rst study to examine SeMet eff ects on 
cell growth and death in GMS-10 and DBTRG-
05MG cells. Our fi ndings indicate that SeMet induces 
cell death at high doses, but increases cell proliferation 
at low doses. Altogether, SeMet appears to be a promis-
ing agent for GBM therapy, and the therapeutic poten-
tial of SeMet, alone or in combination with conven-
tional treatment agents, warrants additional studies.
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Sažetak
IN VITRO UČINCI SELENA NA STANIČNE LINIJE HUMANOG GLIOBLASTOMA MULTIFORME: 
PRELIMINARNO ISTRAŽIVANJE
D. Harmanci, Z. Erbayraktar, O. Sayin i G. Akdogan Guner
Glioblastom multiforme (GBM) uzrokuju glijalne stanice podrijetlom iz središnjega živčanog sustava i to je najčešći 
(50%-60%) oblik primarnog tumora mozga. Cilj ovoga istraživanja bio je ispitati in vitro učinke selena na stanice humanog 
GBM. Rabili smo stanične linije GMS-10 i DBTRG-05MG humanog GBM kao model za ispitivanje ulaska selena u sta-
nicu, stanične proliferacije, citotoksičnosti, fragmentacije DNA i izraženosti proteina Ki-67 u skupini tretiranoj selenome-
tioninom i skupini bez takve obrade. Seleno-L-metionin (SeMet) kao organski izvor selena utjecao je na staničnu prolifera-
ciju i citotoksičnost, što je procijenjeno pomoću testova WST-1 odnosno laktat dehidrogenaze (LDH). Apoptoza je procije-
njena fragmentacijom DNA testom ELISA. Izražajnost proteina Ki-67 utvrđena je Western blotingom, dok su mjerenja 
selena provedena u supernatantima, a lizati primjenom GFAAS. Ovo je prvo istraživanje u kojem su se ispitivali učinci 
 SeMet na staničnu proliferaciju i smrt u stanicama GMS-10 i DBTRG-05MG. Obje stanične linije GBM pokazale su o 
dozi i vremenu ovisan odgovor na SeMet. Test WST-1 pokazao je da je tretman niskom dozom SeMet (50 i 100 μM) pove-
ćao proliferaciju stanica. Rezultati analize unutarstaničnih razina SeMet pomoću AAS bili su sukladni rezultatima testova 
stanične životnosti i citotoksičnosti. Tretman pomoću SeMet kroz 72 h uzrokovao je povećanu fragmentaciju DNA u objema 
staničnim linijama. U zaključku, naši rezultati ukazuju na to da SeMet u visokim dozama izaziva staničnu smrt, dok u niskim 
dozama povećava staničnu proliferaciju. U svjetlu podataka dobivenih u ovom istraživanju smatramo da bi bilo opravdano 
daljnja istraživanja usredotočiti na moguću primjenu SeMet kod različitih tipova GBM i u kombinaciji s mogućim sinergi-
stičnim spojevima.
Ključne riječi: Glioblastom – terapija; Antikancerogeni lijekovi; Ljudi; Selen; Selenometionin; Stanična proliferacija – učinci 
lijekova; Stanična smrt – učinci lijekova; antigen Ki-67
